| Abstrakt: |
A recent study conducted by researchers from Peking University School of Basic Medical Sciences in Beijing, China, investigated the safety and preliminary efficacy of YSCH-01, a recombinant L-IFN adenovirus, in patients with advanced solid tumors. The study involved 14 patients and consisted of two phases: dose escalation and dose expansion. The results showed that YSCH-01 injections were well tolerated and exhibited preliminary efficacy, supporting further investigation into its efficacy and safety. The most common adverse events reported were fever, nausea, vomiting, and hypophagia. [Extracted from the article] |
